J P Morgan Chase & Co reissued their neutral rating on shares of AstraZeneca plc (LON:AZN) in a research note published on Wednesday.

Other analysts have also recently issued research reports about the company. Citigroup Inc. reiterated a buy rating on shares of AstraZeneca plc in a research report on Wednesday, July 5th. Kepler Capital Markets reiterated a buy rating and set a GBX 5,500 ($72.58) price objective on shares of AstraZeneca plc in a research report on Thursday, July 13th. Liberum Capital reiterated a buy rating and set a GBX 5,500 ($72.58) price objective on shares of AstraZeneca plc in a research report on Thursday, July 13th. Deutsche Bank AG reiterated a buy rating and set a GBX 5,700 ($75.22) price objective on shares of AstraZeneca plc in a research report on Friday, July 28th. Finally, Berenberg Bank set a GBX 5,500 ($72.58) price objective on AstraZeneca plc and gave the company a buy rating in a research report on Friday, July 28th. Three investment analysts have rated the stock with a sell rating, seven have given a hold rating and twelve have given a buy rating to the company’s stock. AstraZeneca plc presently has a consensus rating of Hold and an average price target of GBX 5,183.55 ($68.40).

Shares of AstraZeneca plc (AZN) opened at GBX 5,157.64 ($68.06) on Wednesday. AstraZeneca plc has a 1 year low of GBX 3,996 ($52.73) and a 1 year high of GBX 5,520 ($72.84).

COPYRIGHT VIOLATION NOTICE: “AstraZeneca plc (AZN) Earns “Neutral” Rating from J P Morgan Chase & Co” was originally published by Watch List News and is owned by of Watch List News. If you are reading this article on another site, it was copied illegally and republished in violation of US and international copyright & trademark laws. The correct version of this article can be read at https://www.watchlistnews.com/astrazeneca-plc-azn-earns-neutral-rating-from-j-p-morgan-chase-co/1679837.html.

About AstraZeneca plc

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.

Analyst Recommendations for AstraZeneca plc (LON:AZN)

Receive News & Ratings for AstraZeneca plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca plc and related companies with Analyst Ratings Network's FREE daily email newsletter.